Lobbying disclosures · Lobbying report
DHR: second_quarter 2026 lobbying report
Issues pertaining to the regulation of cell and gene therapy products; Issues pertaining to the biomedical research enterprise Issues pertaining to the regulation of cell and gene therapy products; Issues pertaining to the biomedical research enterprise
Follow DHR- Became public
- May 18, 2026, 1:27 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 9, 2026, 12:28 PM EST
Why this is connected
Legal-name match: DANAHER CORPORATION is DANAHER CORP /DE/ (https://www.sec.gov/Archives/edgar/data/313616/), differing only in punctuation, "the" or suffix spelling (Corp/Corporation).
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/db1d750b-d6f4-44c5-acad-a01d7f2778c8/","filing_uuid":"db1d750b-d6f4-44c5-acad-a01d7f2778c8","filing_type":"RR","filing_type_display":"Registration","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/db1d750b-d6f4-44c5-acad-a01d7f2778c8/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Grace Richardson","dt_posted":"2026-05-18T13:27:38-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"440 1st Street NW","registrant_address_2":"Suite 700","registrant_different_address":null,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":22781,"url":"https://lda.gov/api/v1/registrants/22781/","house_registrant_id":30442,"name":"LEWIS-BURKE ASSOCIATES, LLC","description":"Lobbying and Consulting Firm","address_1":"440 1st Street NW","address_2":"Suite 700","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"REED SKAGGS","contact_telephone":"+1 202-289-7475","dt_updated":"2026-07-13T12:18:35.067037-04:00"},"client":{"id":73166,"url":"https://lda.gov/api/v1/clients/73166/","client_id":73166,"name":"DANAHER CORPORATION","general_description":"For-profit Company - Biomedical Products","client_government_entity":null,"client_self_select":false,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2026-05-08"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Issues pertaining to the regulation of cell and gene therapy products; Issues pertaining to the biomedical research enterprise","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":152328,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ANTHONY","last_name":"PETERSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Director, Sen. Leg. Assistant, Leg. Assistant, Leg. Correspondent/Digital Media Specialist, Staff Assistant, Intern, Congressman Peter J. Visclosky","new":true},{"lobbyist":{"id":152329,"prefix":"ms","prefix_display":"MS.","first_name":"ANJALI","nickname":null,"middle_name":"HELENA","last_name":"TADAVARTHY","suffix":null,"suffix_display":null},"covered_position":"Paid Intern - Washington DC Office of Senator Tina Smith","new":true}],"government_entities":[]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues pertaining to the regulation of cell and gene therapy products; Issues pertaining to the biomedical research enterprise","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":152329,"prefix":"ms","prefix_display":"MS.","first_name":"ANJALI","nickname":null,"middle_name":"HELENA","last_name":"TADAVARTHY","suffix":null,"suffix_display":null},"covered_position":"Paid Intern - Washington DC Office of Senator Tina Smith","new":true},{"lobbyist":{"id":152328,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ANTHONY","last_name":"PETERSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Director, Sen. Leg. Assistant, Leg. Assistant, Leg. Correspondent/Digital Media Specialist, Staff Assistant, Intern, Congressman Peter J. Visclosky","new":true}],"government_entities":[]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Price change after we could observe it
-0.34% DHR
Adjusted closing prices from Nov 10, 2026 to Nov 11, 2026. SPY changed 1.32% over the same dates. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.
Congressional trading in DHR
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 5, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Oct 13, 2026 · disclosed Nov 5, 2026 · Dependent
Traded 7 days before earnings - Sep 25, 2026$1K–$15K
Rep. Kevin Hern (R-OK-1)
$1K–$15K · Traded Sep 2, 2026 · disclosed Sep 25, 2026 · Joint
- Sep 25, 2026$15K–$50K
Rep. Kevin Hern (R-OK-1)
$15K–$50K · Traded Aug 31, 2026 · disclosed Sep 25, 2026 · Joint
- Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Feb 6, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Jan 29, 2026 · disclosed Feb 6, 2026 · Spouse
- Jan 15, 2026$1K–$15K
Rep. Julie Johnson (D-TX-32)
$1K–$15K · Traded Dec 18, 2025 · disclosed Jan 15, 2026 · Joint
- Jan 13, 2026$1K–$15K
Rep. Julia Letlow (R-LA-5)
$1K–$15K · Traded Apr 28, 2025 · disclosed Jan 13, 2026 · filed 260 days later
- Dec 11, 2025$1K–$15K
Rep. Julie Johnson (D-TX-32)
$1K–$15K · Traded Nov 13, 2025 · disclosed Dec 11, 2025 · Joint
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.